$MANE

Durso Timothy August sold $4.7M of MANE

Durso Timothy August (Chief Technical Officer) sold 43,500 shares of Veradermics, Inc (MANE) at an average of $107.82 ($106.71–$111.28, $4.69M total) across 5 trades on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Durso Timothy August
Published Aug 19, 2026, 1:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 1:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MANE
Neutral
medium confidence
Mentioned
$MANE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MANENeutralLow
01

Why it matters

This is a primary disclosure of insider selling by the CTO, executed across five trades at $106.71 to $111.28 per share, totaling about $4.69M, with a stated 10b5-1 plan.

02

Market read

Traders may monitor for sentiment effects from insider selling, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The filing does not state whether the insider retained meaningful exposure beyond the post-sale holdings, nor does it provide context on total compensation or prior sale cadence.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed 2026-08-18 for sales executed 2026-08-17.

Background

The article is an SEC Form 4 insider transaction disclosure for Veradermics, Inc (MANE).

Company-level read

Ticker impact

$MANENeutralMedium confidence
Context

Form 4 shows MANE CTO Durso Timothy August sold 43,500 shares in open-market trades for about $4.69M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a primary-source insider transaction with a stated 10b5-1 plan, and it does not include new company fundamentals, guidance, or regulatory/contract events.

Market effects

No clear sector read-through because the disclosure is company-specific and lacks operational or regulatory details.

None indicated.

None indicated.

Counterpoint

The sale may reflect routine liquidity needs under a scheduled 10b5-1 plan, so it may not signal deteriorating fundamentals.

Key entities

  • Veradermics, Inc

    Company whose insider transaction is disclosed on SEC Form 4.

  • Durso Timothy August

    Chief Technical Officer who sold 43,500 shares in open-market trades.

  • 10b5-1 plan

    Pre-arranged plan cited as Yes, which typically reduces interpretive weight of the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MANEHighAI 8/10

Why This Hair Restoration Biotech's Shares Are Soaring

Veradermics (NYSE: MANE), a biotech company, saw its shares rise 268% post-IPO. Its lead therapy, VDPHL01, showed positive phase 3 trial results, with 78.8% to 85% of patients reporting hair coverage improvements. The drug targets a $30B market for pattern hair loss. The company has $820M in cash and analysts' average price target is $170.

MedAI 9/10

Veradermics’ stock up on male hair loss trial success

Veradermics' stock rose 6% after its Phase III trial for male hair loss drug VDPHL01 met all endpoints, showing significant hair growth vs. placebo. The drug was well-tolerated, with 78.8% and 85.0% of patients reporting improvement in once-daily and twice-daily arms, respectively. Veradermics aims for FDA approval, potentially becoming the first oral pill for pattern hair loss in 30 years.

$MANEHighAI 8/10

Veradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” Treatment

Veradermics (MANE) shares rose 10% after its oral hair-loss pill, VDPHL01, met all primary and secondary goals in a second Phase 3 trial. The pill increased hair count significantly compared to placebo with no serious cardiac events. The company expects 12-month safety data later this year. Veradermics has sufficient cash to potentially reach a launch, according to management.

$MANEHighAI 8/10

Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results

Veradermics (NYSE:MANE) reported positive results from its Phase III trial for VDPHL01 in male pattern hair loss, meeting all endpoints. The trial showed strong growth with mild to moderate adverse events. The company plans to release extension data from Study 302 later this year and expects results from a female pattern hair loss study in 2027. Veradermics has $820 million in cash and is evaluating regulatory filing strategies.